Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease.
Gergis
Usama
U
Weill Cornell Medical College, New York, NY, USA.
Arnason
Jon
J
Yantiss
Rhonda
R
Shore
Tsiporah
T
Wissa
Usama
U
Feldman
Eric
E
Woodworth
Thasia
T
D000741:Anemia, Aplastic / Q000601:surgery*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001706:Biopsy; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007422:Intestines / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008297:Male; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D019947:Receptors, Interleukin-6; C502936:tocilizumab